{
    "nctId": "NCT00093808",
    "briefTitle": "Capecitabine, Vinorelbine, and Trastuzumab in Treating Patients With Metastatic Breast Cancer",
    "officialTitle": "Phase II Study of Capecitabine in Combination With Vinorelbine and Trastuzumab for the First- or Second-LineTreatment of HER2+ Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 47,
    "primaryOutcomeMeasure": "Confirmed Response Rate",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically or cytologically confirmed invasive breast cancer\n\n  * Metastatic disease\n* HER2/neu-positive by immunohistochemistry (3+ by HercepTest\\^\u2122 or equivalent) OR positive for amplification by fluorescent in situ hybridization\n\n  * Testing may be performed in the primary tumor or the metastatic site\n* Received prior anthracycline or taxane as adjuvant therapy or for metastatic disease\n* Measurable disease\n\n  * At least one measurable lesion \u2265 2.0 cm by CT scan or MRI OR \u2265 1.0 cm by spiral CT scan\n  * The following are considered non-measurable disease:\n\n    * Bone lesions\n    * Leptomeningeal disease\n    * Ascites\n    * Pleural/pericardial effusion\n    * Inflammatory breast disease\n    * Lymphangitis cutis/pulmonis\n    * Abdominal masses that are not confirmed and followed by imaging techniques\n    * Cystic lesions\n* No bone metastases as the only evidence of metastasis\n* Previously treated CNS metastases allowed provided disease has been stable for \u2265 the past 3 months\n* Hormone receptor status:\n\n  * Not specified\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 18 and over\n\nSex\n\n* Female or male\n\nPerformance status\n\n* ECOG 0-2\n\nLife expectancy\n\n* At least 12 weeks\n\nHematopoietic\n\n* Absolute neutrophil count \u2265 1,500/mm\\^3\n* Hemoglobin \u2265 8.0 g/dL\n* Platelet count \u2265 100,000/mm\\^3\n* No known uncontrolled coagulopathy\n\nHepatic\n\n* Bilirubin \u2264 3.0 times the upper limit of normal (ULN)\n* One of the following must be true:\n\n  * AST or ALT \u2264 5 times ULN AND alkaline phosphatase normal\n  * Alkaline phosphatase \u2264 5 times ULN AND AST or ALT normal\n  * Alkaline phosphatase \u2264 2.5 times ULN AND AST or ALT \u2264 1.5 times ULN\n* INR \u2264 1.5 times ULN\n\nRenal\n\n* Calcium \u2264 11.5 mg/dL\n* Creatinine \u2264 1.5 times ULN\n* Creatinine clearance \u2265 30 mL/min\n\nCardiovascular\n\n* LVEF \u2265 50% by MUGA or echocardiogram\n* No clinically significant (i.e., active) cardiac disease\n* No congestive heart failure\n* No symptomatic coronary artery disease\n* No myocardial infarction within the past 12 months\n* No cardiac arrhythmia not controlled with medication\n\nGastrointestinal\n\n* Able to take oral medication\n* No lack of physical integrity of the upper gastrointestinal tract\n* No clinically significant malabsorption syndrome\n\nOther\n\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception during and for 30 days after study participation\n* No history of allergy or hypersensitivity to study drugs, drug product excipients, including polysorbate 80, or chemically similar agents\n* No prior unanticipated severe reaction to fluoropyrimidine therapy\n* No know hypersensitivity to fluorouracil\n* No known dihydropyrimidine dehydrogenase deficiency\n* No history of uncontrolled seizures or CNS disorders\n* No clinically significant psychiatric disability that would preclude giving informed consent or study compliance\n* No other serious uncontrolled infection or disease\n* No other malignancy within the past 5 years except cured basal cell skin cancer, carcinoma in situ of the cervix, or contralateral breast cancer\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* Prior adjuvant trastuzumab (Herceptin\\^\u00ae) allowed as adjuvant or first-line therapy for metastatic disease\n* No concurrent immunotherapy\n\nChemotherapy\n\n* See Disease Characteristics\n* No more than 1 prior chemotherapy regimen in the advanced or metastatic (non-adjuvant) setting\n* No prior continuous (\u2265 24 hours) fluorouracil infusion\n* No prior capecitabine\n* No prior oral fluoropyrimidines (e.g., eniluracil and fluorouracil, uracil and tegafur, S1, or emitefur)\n\nEndocrine therapy\n\n* At least 1 day since prior hormonal therapy\n* No concurrent hormonal therapy\n\nRadiotherapy\n\n* More than 4 weeks since prior radiotherapy to the axial skeleton (i.e., skull, spinal column, sternum, or ribs)\n* No concurrent radiotherapy\n\nSurgery\n\n* More than 4 weeks since prior major surgery\n* No prior organ allografts requiring immunosuppressive therapy\n\nOther\n\n* More than 4 weeks since prior investigational drugs\n* No concurrent sorivudine or its chemically related analogues (e.g., brivudine)\n* No concurrent allopurinol, metronidazole, or cimetidine\n* No other concurrent cytotoxic agents\n* No other concurrent investigational drugs\n* No other concurrent anticancer therapy",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}